Third-generation targeted agents, such as osimertinib, and new combination regimens, for example EGFR-TKI erlotinib in combination with anti-angiogenic agent ramucirumab approved for EGFR-mutant NSCLC in 2020, were also gradually being used in the clinical practice (5, 41). Here, EGFR is linked to non-small cell lung carcinoma.